XML 82 R66.htm IDEA: XBRL DOCUMENT v3.24.2
Operating Segments (Tables)
3 Months Ended 12 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Operating Segments    
Schedule of operating segments

    

Three Months Ended

    

March 31, 

    

2024

    

2023

Revenues

  

 

  

Specialized BioTherapeutics

$

117,029

$

155,365

Public Health Solutions

101,813

Total

$

117,029

$

257,178

Income (loss) from Operations

 

  

 

  

Specialized BioTherapeutics

$

(860,604)

$

(910,377)

Public Health Solutions

(45,997)

427

Corporate

 

(1,210,490)

 

(1,240,739)

Total

$

(2,117,091)

$

(2,150,689)

Amortization and Depreciation Expense

 

  

 

  

Specialized BioTherapeutics

$

953

$

1,071

Public Health Solutions

159

178

Corporate

 

476

 

536

Total

$

1,588

$

1,785

Other (Expense) Income, Net

 

  

 

  

Specialized BioTherapeutics

$

7,540

$

6,082

Corporate

 

194,224

 

(62,699)

Total

$

201,764

$

(56,617)

Share-Based Compensation

 

  

 

  

Specialized BioTherapeutics

$

20,672

$

27,427

Public Health Solutions

588

994

Corporate

 

38,701

 

45,213

Total

$

59,961

$

73,634

    

As of

As of

    

March 31, 

December 31, 

    

2024

    

2023

    

Identifiable Assets

 

  

 

  

 

Specialized BioTherapeutics

$

301,709

$

272,099

Public Health Solutions

 

120,475

 

3,976

Corporate

 

7,636,201

 

9,521,251

Total

$

8,058,385

$

9,797,326

For the Years Ended

December 31, 

2023

    

2022

Revenues

  

 

  

Specialized BioTherapeutics

$

395,124

$

31,929

Public Health Solutions

444,235

916,982

Total

$

839,359

$

948,911

Income (loss) from Operations

 

  

 

  

Specialized BioTherapeutics

$

(2,812,303)

$

(7,614,988)

Public Health Solutions

(36,531)

26,612

Corporate

 

(4,849,106)

 

(6,650,528)

Total

$

(7,697,940)

$

(14,238,904)

Amortization and Depreciation Expense

 

  

 

  

Specialized BioTherapeutics

$

3,932

$

10,087

Public Health Solutions

655

1,681

Corporate

 

1,967

 

12,794

Total

$

6,554

$

24,562

Other (Expense) Income, Net

 

  

 

  

Specialized BioTherapeutics

$

25,267

$

102,320

Corporate

 

(235,860)

 

(816,690)

Total

$

(210,593)

$

(714,370)

Share-Based Compensation

 

  

 

  

Specialized BioTherapeutics

$

145,683

$

138,075

Public Health Solutions

4,782

4,804

Corporate

 

219,717

 

190,510

Total

$

370,182

$

333,389

    

As of December 31, 

    

2023

    

2022

Identifiable Assets

 

  

 

  

Specialized BioTherapeutics

$

272,099

$

103,742

Public Health Solutions

 

3,976

 

121,290

Corporate

 

9,521,251

 

14,054,685

Total

$

9,797,326

$

14,279,717